{"url_path":"/sec/tvrd/8-k/2026-07-07/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-07","source_url":"https://www.sec.gov/Archives/edgar/data/1346830/0001104659-26-080930-index.html","accession_number":"0001104659-26-080930","cik":"0001346830","ticker":"TVRD","issuer_name":"Tvardi Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1346830/0001104659-26-080930-index.html","primary_entity_key":"0001346830","primary_entity_name":"Tvardi Therapeutics, Inc."},"word_count":198,"has_tables":true,"body_markdown":"**Item 7.01 Regulation FD Disclosure.**\n\n** **\n\nOn July 7, 2026, Tvardi Therapeutics, Inc. (the\n\"**Company**\") issued a press release entitled \"Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design,\nImproved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement.\" The press release provides certain clinical updates\non TTI-109. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein\nby reference.\n\n \n\nOn July 7, 2026, the Company also made available\nan updated corporate presentation to be used to discuss the clinical updates on TTI-109. A copy of the presentation is attached as Exhibit\n99.2 to this Current Report on Form 8-K.\n\n \n\nThe information in this Item 7.01 of this Current\nReport on Form 8-K (including Exhibits 99.1 and 99.2) is being furnished and shall not be deemed \"filed\" for purposes of Section\n18 of the Securities Exchange Act of 1934, as amended (the \"**Exchange Act**\"), or otherwise subject to the liabilities\nof that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange\nAct, except as expressly set forth by specific reference in such a filing."}